Lepidext, Inc.
Lexington, KY
- UEI
- NQA9H9Z389N4
- CAGE
- 7DZ20
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1122 Oak Hill Dr, Lexington, KY 40505, USA
- Website
- lepidext.com
- Founded
- 2015
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Consumer Staples
- Food, Beverage & Tobacco
- Food Products
- Agricultural Products
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Novoclade, Inc. | Saint Paul, MN | — |
| Innatrix Inc. | Cary, NC | 541990 All Other Professional, Scientific, and Technical Services |
| Agrospheres, Inc. | Charlottesville, VA | 562910 Remediation Services |
| Isca Technologies, Inc. | Riverside, CA | 325320 Pesticide and Other Agricultural Chemical Manufacturing |
| Entomology | Santa Clara, CA | — |
About the company
Lepidext, Inc., a for-profit manufacturer based in Lexington, Kentucky, develops and commercializes viral biopesticide products for agricultural pest control, operating exclusively as a prime recipient of federal research grants rather than as a federal contractor. The company holds no prime contracts, IDIQs, or BPAs; its entire federal footprint consists of seven grants from agricultural and scientific agencies, all awarded since 2018.
Lepidext's capability portfolio centers on InsterushZ, a sexually transmitted nudivirus that sterilizes adult moths to suppress pest populations without chemical residues. The company has received five grants totaling $1.8 million obligated across the National Science Foundation, the U.S. Department of Agriculture's National Institute of Food and Agriculture (NIFA), and the Animal and Plant Health Inspection Service (APHIS). Representative work includes an NSF Technology, Innovation, and Partnerships SBIR Phase I grant of $305,000 (July 2026 to June 2027) to accelerate discovery of species-specific sterilizing viral biopesticides for corn earworm and other agricultural pests; an NSF Engineering grant of $256,000 (January to December 2022) for oral delivery systems development; an NSF-funded SBIR Phase I STTR project of undisclosed value (July 2023 to June 2025) to prove InsterushZ feasibility in Hawaii seed corn production; an NIFA project grant (September 2024 to August 2027) focused on scaling production methods for commercial viability in the $12 billion seed corn market; and an APHIS cooperative agreement (September 2024 to September 2025) to develop InsterushZ as a control strategy against invasive Helicoverpa armigera cotton bollworm through transmission via sterile corn earworm moths.
Customer concentration is split among five agencies, with NIFA and NSF each accounting for multiple recent awards. Two grants (combined potential value not specified in source) reach ultimate completion within the next twenty-four months, creating recompete exposure in 2025 and 2027. Lepidext operates entirely in the prime-grant space with no subcontracting role and no federal contract or vehicle positioning; the company competes for SBIR Phase I and Phase II awards and agency-specific project grants rather than on indefinite-delivery vehicles or set-aside contract schedules.
Quick answers
Is Lepidext, Inc. registered in SAM.gov?
Yes. Lepidext, Inc.'s SAM.gov registration is active through December 16, 2026.
What is Lepidext, Inc.'s most recent federal award?
Lepidext, Inc.'s most recent federal grant award is Sbir phase i: accelerated discovery of species-specific sterilizing viral biopesticides (2537778), from National Science Foundation, on July 1, 2026.
On GovTribe
See Lepidext, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors